Latest 8-K filings

TON Strategy Company announced robust second quarter 2026 financial results, highlighted by a significant increase in staking revenue and substantial reductions in operating costs.

Enviri Corporation announced its second quarter 2026 results, reporting a GAAP consolidated loss of $297 million, largely due to charges from exiting Harsco Rail ETO contracts and other restructuring costs, though Adjusted EBITDA showed improvement.

Theriva Biologics announced second quarter 2026 financial results and provided updates on its VCN-01 clinical programs, including patient dosing in the VIRAGE2 Phase 2a study for metastatic pancreatic cancer.

Butterfly Network, Inc. announces the resignation of Dr. Erica Schwartz from its Board of Directors, effective August 5, 2026, following her confirmation as Director of the Centers for Disease Control and Prevention.

Mereo BioPharma Group plc has entered into an option and license agreement with Sentynl Therapeutics, Inc. for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Adamas Trust, Inc. announced an 11.1% increase in its quarterly common stock dividend to $0.30 per share, reflecting confidence in its financial position and outlook.

ManpowerGroup Inc. announced the appointment of John B. Gibson, Jr., President and CEO of Paychex, Inc., to its Board of Directors, effective September 1, 2026.

LB Pharmaceuticals announced accelerated topline data for its LB-102 schizophrenia trial, plans pipeline expansion, and secured $150 million in funding.

Protara Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical trials for TARA-002 and IV Choline Chloride, with a cash runway extending into 2028.

Kalaris Therapeutics announced second quarter 2026 financial results, reporting $93.5 million in cash and ongoing patient dosing in its Phase 1b/2 study for TH103, with preliminary data anticipated in 1H 2027.

Neuronetics, Inc. announced its second quarter 2026 financial and operating results, highlighting a 9.1% increase in total revenue and a significant reduction in net loss.

Coya Therapeutics reported Q2 2026 results, noting progress in its ALSTARS Phase 2 ALS trial, FDA Fast Track designation for COYA 302, and plans for a new FTD study, while managing a net loss of $6.6 million.

Imunon, Inc. announced its second quarter 2026 financial results, highlighting strong enrollment in its Phase 3 OVATION 3 study for IMNN-001 and positive preliminary data from a minimal residual disease study.

Smithfield Foods announced record first half fiscal 2026 operating profit, driven by its vertically integrated model, despite a slight dip in net sales.

Big Sky Industrial Inc. announced strong Q2 2026 results, highlighting construction progress at its Carbon Hub, a five-year take-or-pay helium offtake agreement, and a corporate rebrand to BSIN.

1606 Corp. has entered into a strategic agreement with MDM Group LLC to market its 132-acre East Texas power campus to AI infrastructure operators and strategic buyers.

Hanmi Financial Corporation presented its Q2 2026 operating and financial performance, highlighting steady loan and deposit growth, robust capital ratios, and a diversified loan portfolio.

Terrestrial Energy Inc. reported significant progress in its IMSR reactor development, including NRC approval of key licensing documents and updated economic projections showing increased lifetime revenue per plant.

Joby Aviation announced its definitive agreement to acquire Resonant Sciences for approximately $500 million, aiming to scale its defense business and create a diversified growth platform.

Stardust Power Inc. announced the appointment of V. Ray Rivers, a seasoned capital markets and financial services executive, to its Board of Directors, effective August 10, 2026.

Prelude Therapeutics announced its second quarter 2026 financial results, highlighting progress in its oncology pipeline and a cash runway extending into Q2 2028.

Peabody Energy provided an update on its Centurion Mine, detailing progress in overcoming operational challenges and emphasizing its strategic importance in the metallurgical coal market.

Unusual Machines announces an investor presentation detailing accelerated growth strategies, a pending acquisition, and significant market opportunities driven by US drone manufacturing initiatives.

ClearSign Technologies Corporation announced the appointment of Larry M. Saddler, a former Global Technology Sponsor for Heat Transfer at ExxonMobil, to its Board of Directors, effective August 6, 2026.

Intensity Therapeutics announced the resumption of enrollment in its Phase 3 soft tissue sarcoma study and restarted patient treatment in its Phase 2 triple-negative breast cancer trial, alongside its second quarter 2026 financial results.

Bicara Therapeutics reports Q2 2026 progress, including strong enrollment in its pivotal FORTIFI-HN01 study and a planned CEO transition to Ryan Cohlhepp in January 2027.

Zura Bio announced the completion of enrollment for its TibuSHIELD and TibuSURE Phase 2 studies, with topline data expected in Q4 2026 and H1 2027, respectively, and plans to initiate a new Phase 2 study for tibulizumab in polymyalgia rheumatica by year-end 2026.

Sagimet Biosciences announced its second quarter 2026 financial results, highlighting a robust cash position and progress in its denifanstat and TVB-3567 clinical programs for acne treatment.

Littelfuse, Inc. announced the appointment of Todd Kelsey, CEO of Plexus Corp., to its Board of Directors and Compensation Committee, effective August 6, 2026.

Autolus Therapeutics plc announced robust second-quarter 2026 financial results, driven by significant AUCATZYL sales growth, leading to an increase in full-year revenue guidance and a strengthened financial position.